Trials / Withdrawn
WithdrawnNCT02637375
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy resistance), the study will test a novel approach for improving chemotherapy effectiveness by adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are initiated via GR, AR, and JAK/STAT activation.
Detailed description
STUDY OBJECTIVES Primary: • To determine tumor GR, AR, JAK and other Hsp90 client protein expression before and after two weeks of ganetespib monotherapy Secondary: * To determine the pathological Complete Response (pCR) rate associated with weekly treatment of ganetespib plus paclitaxel followed by the combination treatment of doxorubicin plus cyclophosphamide * To characterize the toxicity of study treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganetespib | |
| DRUG | Paclitaxel | |
| DRUG | Doxorubicin | |
| DRUG | Cyclophosphamide |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-12-22
- Last updated
- 2016-05-30
Source: ClinicalTrials.gov record NCT02637375. Inclusion in this directory is not an endorsement.